Compare Quest Diagnostics Inc (DGX) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SPDR Kensho Final Frontiers ETF — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while SPDR Kensho Final Frontiers ETF trades at $102.84 (market cap $176.19M). The key difference: Quest Diagnostics Inc is far larger — about 142.2× SPDR Kensho Final Frontiers ETF's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while SPDR Kensho Final Frontiers ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and SPDR Kensho Final Frontiers ETF for 8 Days on average.
| DGX | ROKT | |
|---|---|---|
Market Cap | $25.06B | $176.19M |
Volume | 927,361 | 34,479 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $136.68 |
52-Week Low | $173.49 | $72.93 |
Typical Hold Time | 56 Days | 8 Days |
Enterprise Value | $30.82B | — |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
